Pfizer ends COVID-19 vaccine trial with 95% success rate

The results are in for a frontrunner in the race for a COVID-19 vaccine. United States pharma giant Pfizer Inc and its German partner BioNTech said on Wednesday that final results from the Phase 3 trial of their COVID-19 vaccine showed it to be 95 percent effective – the highest success rate for any pandemic candidate in late-stage trials so far.